Multiple Myeloma:
The second issue of Emerging Cancer Therapeutics focuses on multiple myelomas also known as plasma cell myeloma, KahlervÉs Disease and myelomatosis. It is estimated that over 20,000 new cases are diagnosed each year with over 10,000 people dying from these malignancies. Multiple myelomas are highly treatable but rarely curable. Thus it is crucial for the practitioner to be up-to-date on the latest insights regarding their management.
Management options and outcomes for individuals with multiple myelomas improved dramatically with the introduction of chemotherapy. Even further improvements in prognosis have occurred because of the introduction of newer therapies such as pulse corticosteroids, thalidomide, bortezomib, and autologous and allogeneic stem cell transplantation. With the increased number of therapeutic options to choose from, the clinician is better placed to offer effective therapy but at the same time is challenged to keep abreast of the rapidly changing treatment landscape and the newly emerging data that is shaping the treatment options today and in the future. Multiple Myeloma provides a comprehensive and in-depth review of this group of malignancies. This volume reviews the current literature, provides critical evaluations of the data and offers evidence-based recommendations.
About the Series:
Emerging Cancer Therapeutics is an invited review publication providing a through analysis of key clinical research related to cancer therapeutics, including a discussion and assessment of current evidence, current clinical best practice, and likely near future developments. There is an emphasis throughout on multidisciplinary approaches to the specialty, as well as on quality and outcomes analysis. Published three times a year Emerging Cancer Therapeutics provides authoritative, thorough assessments of advances in therapeutics in all major areas of oncology, both solid and hematologic malignancies, with a focus on advances in medical and biological therapies with emerging clinical impact and encompassing new technologies with implications for management such as molecular imaging.
Features of Emerging Cancer Therapeutics include:
Le informazioni nella sezione "Riassunto" possono far riferimento a edizioni diverse di questo titolo.
Book by Shaji Kumar MD Abraham MD FACP Jame
Le informazioni nella sezione "Su questo libro" possono far riferimento a edizioni diverse di questo titolo.
EUR 28,90 per la spedizione da Regno Unito a Italia
Destinazione, tempi e costiEUR 5,77 per la spedizione da Regno Unito a Italia
Destinazione, tempi e costiDa: Mispah books, Redhill, SURRE, Regno Unito
Hardcover. Condizione: Like New. Like New. book. Codice articolo ERICA77319338649156
Quantità: 1 disponibili
Da: UK BOOKS STORE, London, LONDO, Regno Unito
Condizione: Brand New. Brand New! Fast Delivery US Edition and ship within 24-48 hours. Deliver by FedEx and Dhl, & Aramex, UPS, & USPS and we do accept APO and PO BOX Addresses. Order can be delivered worldwide within 7-10 days and we do have flat rate for up to 2LB. Extra shipping charges will be requested if the Book weight is more than 5 LB. This Item May be shipped from India, United states & United Kingdom. Depending on your location and availability. Codice articolo CBS 9781933864914
Quantità: 1 disponibili